RPTX - Repare Therapeutics Inc

RPTX - Repare Therapeutics Inc

https://www.reparerx.com

Recent News

Powered by Alpha Vantage

Repare Therapeutics Inc. ( RPTX ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.11

Repare Therapeutics (RPTX) delivered earnings and revenue surprises of +30.36% and -95.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - ARK Genomic Revolution ETF ( BATS:ARKG ) , ARK Innovation ETF ( BATS:ARKK )

Benzinga • 5 months ago • score: 0.37

On Friday, April 11, 2025, Cathie Wood-led Ark Invest executed notable trades, shedding shares in UiPath Inc. PATH, Prime Medicine Inc. PRME, and Repare Therapeutics Inc. RPTX. Ark Invest's ARK Innovation ETF ARKK fund sold 4,256 shares of UiPath Inc.

Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox - ARK Fintech Innovation ETF ( BATS:ARKF ) , Amazon.com ( NASDAQ:AMZN )

Benzinga • 5 months, 1 week ago • score: 0.35

On Friday, April 4, 2025, Cathie Wood-led Ark Invest made substantial trades involving several prominent companies including Coinbase Global Inc. COIN, Amazon.com Inc. AMZN, CRISPR Therapeutics AG CRSP, Beam Therapeutics Inc. BEAM, UiPath Inc. PATH, Roblox Corp. RBLX, MercadoLibre Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Repair Therapeutics Inc., a precision oncology company, discovers and develops novel therapies using its synthetic lethality approach in Canada and the United States. The company is headquartered in Montral, Canada.

52W High

$4.07

52W Low

$0.89

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.93

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.58

EV/Revenue (<3 favorable)

0.02

P/S (TTM) (<3 favorable)

290.40

P/B (<3 favorable)

0.66

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.25%

Institutions (25–75% balanced)

64.93%

Shares Outstanding

42,959,200

Float

22,715,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

250,000

Gross Profit (TTM)

15,364,000

EPS (TTM)

-2.58

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-80.25%

ROE (TTM) (>15% strong)

-0.70%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.77

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—